卖什么
AI-native pharma company
商业模式拆解
买家：谁掌握预算？
Not a vendor product; pharma-style company partnering with disease foundations (e.g. Alliance to Cure Cavernous Malformation).
工作流：什么输入变成什么输出？
Autonomous agents find FDA-approved drugs to repurpose for new diseases (e.g. cavernous malformation) and run clinical trials efficiently, including agent-based trial success prediction.
经济账：省了什么，怎么收费？
Drug developer: monetizes through owning/developing repurposed drug candidates for long-tail diseases where inference cost replaces knowledge-work cost; no revenue figures stated.
渠道：怎么接触到客户？
Partnerships with patient foundations and preclinical/clinical collaborators; research published via blog and benchmarks (RepurposingBench, ClinicBench).
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| — | YC 2026 夏季 | — | Y Combinator | ycombinator.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.